CD133 significance in glioblastoma development: in silico and in vitro study
Authors:
Open Access
- 6 March 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-12
Abstract
Background: Glioblastoma multiform (GBM) is among the commonly diagnosed brain malignancies with poor prognosis. CD133 has been introduced as an oncogene in various cancers, like GBM. This study aimed to investigate the significance of CD133 in GBM development using in silico and in vitro techniques. Method: The TCGA-GBM database was analyzed for the correlational and comparative studies. After selecting the U87MG cell line, CD133-siRNA was transfected into U87MG cells and treated with temozolomide. The cell viability, cell cycle, migration, clonogenicity, and apoptosis of groups were investigated using MTT, flow cytometry, wound-healing, colony formation, and annexin V/PI assays. Using qRT-PCR method, the mRNA expression levels of MMP16, SOX2, RAF1, MAP2K1, MAPK3, PIK3CA, AKT3, mTOR, CDK4, and BCL2 were studied. Results: CD133 silencing improves apoptosis rate, arrests the cell cycle at the sub-G1 phase, suppresses the clonogenicity of U87MG cells, and inhibits the PI3K/Akt and MAPK pathways via downregulating the RAF1, MAP2K1, MAPK3, PIK3CA, AKT3, and mTOR expression. Besides, combining CD133 silencing with temozolomide treatment considerably inhibits the migration of U87MG cells compared to temozolomide monotherapy. Conclusion: CD133 can regulate the PI3K/Akt and MAPK pathways and modulate the clonogenicity, apoptosis, and cell cycle of GBM. Combining CD133 silencing with temozolomide treatment considerably increases apoptosis, arrests the cell cycle at the sub-G1, and suppresses migration of U87MG cells compared to temozolomide monotherapy. GraphicalKeywords
This publication has 44 references indexed in Scilit:
- The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapyBiomedicine & Pharmacotherapy, 2021
- The oncogenic potential of NANOG: An important cancer induction mediatorJournal of Cellular Physiology, 2020
- CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxelMolecular Biology Reports, 2020
- Quantitative Proteomics of the Cancer Cell Line EncyclopediaCell, 2020
- A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cellsCellular Oncology, 2018
- CD133 Is Essential for Glioblastoma Stem Cell MaintenanceStem Cells, 2013
- Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cellsNeuroscience Letters, 2010
- Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinomaJournal of Hepatology, 2010
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitroGlia, 2002